top of page

Welcome to DoricPharma LLC

Science
Home: Overview
Pipetting Samples

Research

We are contributing to the fight to eradicate cancer 

We are using targeted lipid nanoparticles, TLNs, to selectively bring chemotherapy only to cancer and avoid healthy tissues. TLNs eradicate cancer with minimal adverse-effects.  Our goal is to extend and enhance the quality of life of cancer patients. 

Home: Research
Scientist in the Lab

Delivering the Chemotherapy Only to Tumor

DoricPharma has a patented drug delivery platform, Targeted Lipid Nanoparticles, TLNs. TLNs deliver chemotherapeutics selectively only to tumors, thereby sparing the healthy organs from the adverse-effects of the chemotherapy. TLNs maintain prolonged concentrations of chemotherapeutics in tumors while improving their therapeutic efficacy and reducing their adverse effects.

Molecule_edited_edited.jpg

TLNs in Pancreatic Cancer

The TLNs drug delivery technology has been shown to target pancreatic tumors in mice, deliver the drug over an extended period of time, and significantly reduce or obliterate orthotopic or subcutaneous orthotopic tumors in mice.

Misty Slope

Intellectual Property

Doric Pharma's TLNs technology is supported by US and international patents

Home: Publications

Country and Patent Number 

​

USA              US9808425

Canada         2,846,670

Europe          12830510

​

​

​

​

Country  and  Patent Number

Japan              6258202

China              202180043744.0

Israel               230,987

​

Misty Slope

We thank NIH/NCI for their support:

R41CA247009-01, PI: Lambros, M., $299,559

    R41CA247009-01S1, PI: Lambros, M., $102,195

   R41CA247009-01S2, PI: Lambros, M.,  $52,000

​

​

Home: Testimonial Form

The Team

Home: Lab Members
Mike%20NIcolaou_edited.jpg

Mike Nicolaou, PhD

CEO and Manager of Operations

Dr Nicolaou is a Pharmaceutical Chemist with 23 years of industrial experience in pharmaceutical industry. He has worked in the areas of product development, manufacturing and quality control and contributed to four new commercial pharmaceutical products in the areas of diabetes and metabolic diseases, and a vaccine product currently in clinical trials in the area of oncology.

Contact Us

​

Lab: 

Irvine CA, 92617

Petri Dish
Home: Contact

©2022 by DoricPharma LLC. Proudly created with Wix.com

bottom of page